Welcome to our dedicated page for Cyclerion Therapeutics news (Ticker: CYCN), a resource for investors and traders seeking the latest updates and insights on Cyclerion Therapeutics stock.
Cyclerion Therapeutics, Inc. (CYCN) is a Nasdaq-listed clinical-stage biopharmaceutical company that provides frequent updates on its progress in neuropsychiatric drug development and the monetization of its legacy soluble guanylate cyclase (sGC) portfolio. This news page aggregates company press releases and market-moving announcements so readers can follow how Cyclerion’s strategy and pipeline evolve over time.
Recent news highlights Cyclerion’s transformation into a neuropsychiatric company, centered on an individualized therapy for treatment-resistant depression (TRD). The company has reported a license agreement with the Massachusetts Institute of Technology for technology to treat neuropsychiatric disorders and has announced CYC-126, an anesthetic-based investigational therapy that uses real-time EEG monitoring and algorithm-guided dosing, as its lead program for TRD.
Investors and observers can also track Cyclerion’s collaboration and business development activity. Updates include an application-specific, exclusive collaboration with Medsteer SAS to integrate closed-loop anesthetic delivery technology into CYC-126, as well as agreements to sell or license legacy sGC assets such as zagociguat, CY3018, praliciguat, and olinciguat. These items illustrate how the company aims to generate non-dilutive funding while building its neuropsychiatric pipeline.
In addition, the news flow covers corporate governance and capital markets developments, including board appointments, leadership changes, reverse stock split actions, and Nasdaq listing compliance updates. By reviewing this page regularly, readers can follow Cyclerion’s clinical plans, partnership announcements, licensing milestones, and strategic updates that may influence the CYCN stock narrative.
Cyclerion Therapeutics (Nasdaq: CYCN) announced its management will attend the Jefferies London Healthcare Conference from Nov. 16-18, 2021. A pre-recorded presentation will be available on-demand starting Nov. 18 for 30 days on their investor website. Cyclerion focuses on developing treatments for cognitive function, with their leading compound, CY6463, showing promise in clinical trials for various CNS diseases, including Alzheimer's Disease with vascular pathology. They are also advancing another compound, CY3018.
Cyclerion Therapeutics reported advancements in its lead investigational candidate, CY6463, designed for cognitive disorders, in its Q3 2021 results. Enrollment has begun in clinical studies for Cognitive Impairment Associated with Schizophrenia (CIAS), Alzheimer's with vascular issues (ADv), and MELAS, with clinical data anticipated in H1 2022. As of September 30, 2021, the company held approximately $63 million in cash, down from $70 million in June. R&D and G&A expenses decreased significantly, contributing to an improved net loss of $11.3 million compared to $18.8 million in Q3 2020.
Cyclerion Therapeutics announces progress in developing CY6463, a soluble guanylate cyclase (sGC) stimulator aimed at treating CNS diseases linked to cognitive impairment. Recent preclinical studies showed that CY6463 effectively reduces neuroinflammation markers and crosses the blood-brain barrier. The results, published in the Journal of Neuroinflammation, support CY6463's potential as a therapeutic solution for conditions like Alzheimer's. Cyclerion is advancing its clinical studies, focusing on gauging significant clinical benefits for patients suffering from these serious conditions.
Cyclerion Therapeutics (NASDAQ: CYCN) has announced participation in two upcoming investor conferences. The H.C. Wainwright 23rd Annual Global Investment Conference will be held from September 13-15, 2021, featuring an on-demand session starting September 13 at 7:00 a.m. EDT. Additionally, the Cantor Fitzgerald Virtual Global Healthcare Conference is scheduled for September 30, 2021, at 2:40 p.m. EDT. Live webcasts can be accessed through the Investors & Media section of Cyclerion's website, with archived versions available for 90 days.
Cyclerion Therapeutics announces participation in the Annual Biomarkers for Alzheimer's Disease Summit on August 25-26, 2021. Presenters include Chris Winrow, Ph.D., discussing early clinical assessment of biomarkers for Alzheimer’s therapies, and Juli Jones, Ph.D., focused on omics platforms in drug discovery. Key presentations occur on August 25 at 4:20 p.m. ET and August 26 at 2:30 p.m. ET, followed by a Q&A. Cyclerion is advancing CY6463, targeting cognitive function restoration in diseases like Alzheimer's and schizophrenia.
Cyclerion Therapeutics reported significant advancements in clinical development for CY6463, a CNS-penetrant sGC stimulator, targeting Alzheimer's disease with vascular pathology (ADv) and related conditions. The FDA approved the IND application for CY6463, initiating a 12-week Phase 2a trial in ADv. Cyclerion raised approximately $30.5 million through private placements and an ATM offering in Q2 2021. The net loss decreased to $16.2 million from $19.5 million year-over-year. The company is also progressing CY3018 and has partnerships aimed at enhancing clinical developments.
Cyclerion Therapeutics (Nasdaq: CYCN) is set to present its Phase 2a study design for its lead candidate, CY6463, targeting Alzheimer’s disease with vascular pathology at the Alzheimer’s Association International Conference 2021, occurring from July 26-30, 2021. The research showcases neuropsychological biomarkers as predictors of cognitive performance in Alzheimer's patients. Cyclerion's innovative approach aims to restore cognitive function, as the company continues to advance treatments for various CNS disorders, with CY6463 demonstrating promise in earlier studies.
Cyclerion Therapeutics (Nasdaq: CYCN) and Beacon Biosignals have expanded their strategic partnership to enhance the development of Cyclerion's therapeutics targeting neurological diseases linked to cognitive impairment. Utilizing Beacon's EEG neurobiomarker platform, the collaboration aims to identify biomarkers for better patient selection and clinical endpoints. Cyclerion’s lead candidate, CY6463, has shown promising impacts on EEG parameters and is being evaluated in various ongoing studies, including those for Alzheimer's disease and schizophrenia.
Cyclerion Therapeutics (Nasdaq: CYCN) has announced an expanded strategic partnership with Beacon Biosignals to enhance data collection and analytics for developing investigational therapeutics targeting neurological diseases linked to cognitive impairment. This collaboration aims to identify relevant biomarkers and improve patient selection for Cyclerion's clinical studies, including those for CY6463, a CNS-penetrant sGC stimulator. Ongoing studies focus on conditions like Alzheimer’s with vascular pathology and cognitive impairment associated with schizophrenia.
Cyclerion Therapeutics has entered a global licensing agreement with Akebia Therapeutics for the development of praliciguat, a treatment for kidney disease. Cyclerion is set to receive up to $585 million in potential milestone payments and tiered royalties. This deal allows Cyclerion to concentrate on its key projects, CY6463 and CY3018, which target cognitive impairment. The agreement positions Cyclerion to benefit from Akebia's expertise in kidney disease, enhancing its strategic focus on developing CNS therapies.